| Literature DB >> 32171167 |
Nathalie Hensiek1, Frank Schreiber2, Thomas Wimmer1, Jörn Kaufmann1, Judith Machts2, Laura Fahlbusch1, Cornelia Garz2, Susanne Vogt2, Johannes Prudlo3, Reinhard Dengler4, Susanne Petri4, Peter J Nestor5, Stefan Vielhaber6, Stefanie Schreiber7.
Abstract
A few systematic imaging studies employing ultrasound (HRUS) and magnetic resonance imaging (MRI) have suggested tongue measures to aid in diagnosis of amyotrophic lateral sclerosis (ALS). The relationship between structural tongue alterations and the ALS patients' bulbar and overall motor function has not yet been elucidated. We here thus aimed to understand how in-vivo tongue alterations relate to motor function and motor function evolution over time in ALS. Our study included 206 ALS patients and 104 age- and sex-matched controls that underwent HRUS and 3T MRI of the tongue at baseline. Sonographic measures comprised coronal tongue echointensity, area, height, width and height/width ratio, while MRI measures comprised sagittal T1 intensity, tongue area, position and shape. Imaging-derived markers were related to baseline and longitudinal bulbar and overall motor function. Baseline T1 intensity was lower in ALS patients with more severe bulbar involvement at baseline. Smaller baseline coronal (HRUS) and sagittal (MRI) tongue area, smaller coronal height (HRUS) and width (HRUS) as well as more rounded sagittal tongue shape predicated more rapid functional impairment - not only of bulbar, but also of overall motor function - in ALS. Our results suggest that in-vivo sonography und MRI tongue measures could aid as biomarkers to reflect bulbar and motor function impairment.Entities:
Keywords: Amyotrophic lateral sclerosis; Biomarker; Intensity; MRI; Prognosis; Tongue; Ultrasound
Year: 2020 PMID: 32171167 PMCID: PMC7068685 DOI: 10.1016/j.nicl.2020.102233
Source DB: PubMed Journal: Neuroimage Clin ISSN: 2213-1582 Impact factor: 4.881
Demographics of the sample under consideration.
| Total cohort | MRI cohort | HRUS cohort | ||||||
|---|---|---|---|---|---|---|---|---|
| ALS | CON | ALS | CON | p | ALS | CON | p | |
| Age in years** | 63 (32;83) | 61 (33;83) | 62 (32;83) | 62 (33;83) | 1.0 | 65 (45;81) | 58 (50;77) | 0.052 |
| Male sex, n (%)*** | 129 (63) | 64 (62) | 110 (63) | 55 (63) | 1.0 | 30 (63) | 9 (53) | 0.5 |
| Height in cm*, mean [SD] | 172 [9] | 173 [10] | 172 [10] | 174 [9] | 0.4 | 172 [8] | 172 [11] | 1.0 |
| Weight in kg*, mean [SD] | 74 [14] | 80 [13] | 74 [14] | 80 [13] | 0.1 | 76 [16] | 80 [14] | 0.3 |
Unless otherwise reported median (range) is given. For group comparisons independent-samples t-test*, Mann-Whitney U test** or χ² test*** was conducted. P-values <0.05 were deemed statistically significant.
ALS, amyotrophic lateral sclerosis; CON, controls; HRUS, high-resolution ultrasound; MRI, magnetic resonance imaging.
Clinical data of the ALS sample under consideration.
| Total ALS cohort | MRI ALS cohort | HRUS ALS cohort | ||
|---|---|---|---|---|
| Limb onset, n (%)** | 139 (67) | 115 (66) | 37 (77) | 0.4 |
| Classic ALS, n (%)** | 134 (65) | 116 (66) | 27 (56) | 0.2 |
| LMND ALS, n (%)** | 41 (20) | 33 (19) | 13 (27) | 0.3 |
| UMND ALS, n (%)** | 21 (10) | 16 (9) | 6 (13) | 0.5 |
| PLS, n (%)** | 10 (5) | 9 (5) | 2 (4) | 0.7 |
| Disease duration from symptom onset to imaging in months* | 17 (0.7;272) | 16 (3;272) | 22 (0.7;148) | 0.5 |
| Duration from diagnosis to imaging in months* | 5 (0;122) | 5 (0;122) | 3 (0;124) | 0.1 |
| ALSFRS-R total baseline* | 39 (13;48) | 40 (14;48) | 36 (8;46) | 0.04 |
| ALSFRS-R bulbar baseline* | 11 (1;12) | 11 (1;12) | 11 (0;12) | 0.8 |
| Last available ALSFRS-R total* | 34 (3;47) | 35 (3;47) | 29 (7;46) | 0.2 |
| ALSFRS-R total decline* | 9 (0;37) | 9 (0;37) | 9 (0;23) | 0.6 |
| Last available ALSFRS-R bulbar* | 10 (0;12) | 10 (0;12) | 9 (0;12) | 0.9 |
| ALSFRS-R bulbar decline* | 1 (0;9) | 1 (0;9) | 0 (0;7) | 0.4 |
| NIV, n (%)** | 18 (9) | 10 (4) | 10 (15) | 0.03 |
| PEG, n (%)** | 11 (5) | 5 (2) | 6 (9) | 0.04 |
| Familial ALS, n (%)** | 17 (10) | 17 (11) | 2 (8) | 0.5 |
Unless otherwise reported median (range) is given. Decline of ALSFRS-R total score and bulbar sub-score was determined through subtracting the respective baseline minus the last available score in terms of longitudinal follow-up. Concerning the ALSFRS-R total (bulbar sub-score) decline n = 118 (114) ALS patients were available. For group comparisons Mann-Whitney U test* or χ²** test has been conducted. Statistics relate to the comparison of the MRI ALS cohort against the HRUS ALS cohort. P-values <0.05 were deemed statistically significant.
ALS, amyotrophic lateral sclerosis; ALSFRS-R, revised ALS functional rating scale; HRUS, high resolution ultrasound; LMND, lower motor neuron dominant; MRI, magnetic resonance imaging; NIV, non-invasive ventilation; PEG, percutaneous endoscopic gastrostomy; PLS, primary lateral sclerosis; UMND, upper motor neuron dominant.
Fig. 1Sonographic examination of the tongue (coronal plane). Subfigure (a) demonstrates the anatomical boundaries of the tongue while (b) shows the tongue as a region of interest (ROI) obtained after manual delineation and then used to calculate various tongue measures (mean echointensity, area, coronal width, coronal height, height/width).
Fig. 2T1 weighted 3T MRI of the tongue (sagittal plane). Subfigure (a) shows the tongue ROI (TR) and the reference ROI (RR) as well as the latter's anatomical boundaries. Subfigure (b) demonstrates indicators of abstracted properties used for the evaluation of the tongue's shape and position.
Fig. 3MRI-based T1 intensity at baseline (sagittal plane). Subfigure (a) demonstrates the correlation between T1 intensity and ALSFRS-R bulbar sub-score. Subfigure (b) demonstrates the mean [SD] T1 intensity of bulbar- compared to limb-onset ALS patients. *p < 0.001.
Fig. 4Longitudinal ALSFRS-R total score as a function of baseline sonographic tongue measures. Graphs demonstrate significant time interaction effects of baseline sonographic tongue area (a), width (b) and height (c) on longitudinal ALSFRS-R total score. ALS patients revealing larger baseline sonographic measures (black) compared to patients displaying smaller baseline sonographic measures (red) declined slower when considering the longitudinal ALSFRS-R total score. ALSFRS-R, revised ALS functional rating scale.